UK Approves Breakthrough Breast Cancer Drug Enhertu for NHS Use Following Cost Settlement

London, Friday, 18 September 2026.
In September 2026, health authorities approved the life-extending drug Enhertu for NHS England, nearly doubling disease progression-free survival for around 1,000 patients following updated commercial and valuation framework agreements.